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Abstract
We report a case of a 66-year-old severely osteoporotic woman with bisphosphonate-related osteonecrosis of the
jaw (BRONJ) around her dental implants, who was treated successfully with teriparatide and sequestrectomy of the
mandible. After 5 months of teriparatide therapy, the sequestrum separation had progressed and a sequestrectomy
was performed under general anesthesia. Five months after the operation, new bone formation was observed
around the bone defect in the region of the sequestrectomy. A repeat computed tomographic image revealed
improvement in the bone defect in the mandible. These results suggest that teriparatide provides beneficial effects
in the treatment of advanced BRONJ around dental implants.
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Background
Oral bisphosphonates (BPs) are used to treat osteoporosis,
Paget’s disease, and osteogenesis imperfecta. They are
most widely used for treatment of osteoporosis. BP-
related osteonecrosis of the jaw (BRONJ) was first
reported by Marx in 2003 [1]. The risk of BRONJ in osteo-
porotic patients treated with BPs remains low compared
with that of oncology patients [2]. Recent studies have in-
dicated that the relative incidence of BRONJ in patients
with osteoporosis is higher than previously thought [3].
Madrid and Sanz [4] suggested that the placement of den-
tal implants in patients treated with oral bisphosphonates
was not associated with the onset of BRONJ; they found
no relationship between the treatment and the survival of
implants. However, more recently, an increasing number
of peri-implant BRONJ cases have been described [5–9].
Peri-implant BRONJ currently is considered an additional
complication related to oral implants, along with nerve
injury, bleeding, sinus perforation, implant ingestion/as-
piration, peri-implantitis, and mucositis [6].
We present a case of a severely osteoporotic woman
with BRONJ around her dental implants, who was treated
successfully with teriparatide and sequestrectomy.
Case presentation
A 66-year-old woman was referred to the Oral and
Maxillofacial Surgery Clinic at Hyogo College of Medi-
cine Hospital, Japan, in September 2011, for an extraoral
fistula and refractory pain of the right mandible associ-
ated with a purulent discharge and soft tissue swelling.
The patient’s osteoporosis was diagnosed in 2005 and
treated with 35 mg of alendronate weekly by the family
doctor. The patient had a past history of severe osteo-
porosis, multiple vertebral fractures, and renal failure.
She had taken 20 mg of prednisone for 3 months from
2005 for the treatment of IgA nephropathy.
Dental implant treatment in the maxilla and mandible
was begun in June 2009 by the family dentist. Five im-
plants (Spline Twist implant, Zimmer Dental, Carlsbad,
CA) were placed at the same time in the posterior region
of the mandible. The surgical procedure was uneventful,
and primary stability of the implants was achieved. In
September 2010, at the time of implant reopening for the
second surgery, the implants had integrated and the
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healing abutments were connected. Provisional maxillary
and left mandibular prostheses were cemented onto the
abutments.
Nine months after the second surgery in June 2011,
the patient started to complain of a painful cheek swell-
ing on the right side of the mandible, associated with
gingival bleeding. She was prescribed oral antibiotics by
her dentist and underwent occasional antibiotic therapy
thereafter.
In September 2011, the patient was referred to our
clinic because her symptoms were getting worse. Clinical
examination revealed an intraoral fistula on the lingual
side of the dental implant replacing the right mandibular
first molar, associated with mucosal inflammation and a
purulent discharge (Fig. 1a, b). She also had hypoesthesia
of the right lower lip. The patient underwent panoramic
radiography (Fig. 2a) and computed tomography (CT),
which showed bone resorption around the dental im-
plant in the right mandibular first molar area and severe
peri-implantitis in the right mandibular molar region.
There was no obvious sequestrum separation (Fig. 2b, c).
Under a clinical diagnosis of perimandibular inflammation
and peri-implantitis, conservative treatment consisting of
local irrigation and use of antibiotics was implemented.
Meropenem hydrate was given initially, then changed to
ampicillin/sulbactam. The inflammatory state improved,
and when the symptoms subsided, treatment with clari-
thromycin was continued. Debridement and removal of
the dental implant in the right mandibular first molar area
was performed under local anesthesia. Irrigation of the site
was continued as part of the treatment regimen.
In November 2011, after a consultation with an osteo-
porosis expert at the Orthopedic Medicine Clinic of our
hospital, alendronate therapy was stopped and subcuta-
neous teriparatide therapy at a dose of 20 μg per day
was started. During the course of the teriparatide ther-
apy, the patient continued to use 0.02% benzalkonium
chloride solution for local irrigation.
In April 2012, after 5 months of teriparatide therapy,
the sequestrum separation had progressed (Fig. 3), and a
sequestrectomy was performed under general anesthesia
(Fig. 4). At 5 months after the operation, a CT scan re-
vealed new bone formation around the bone defect in
the region of the sequestrectomy, with all symptoms
including bone exposure disappearing (Fig. 5). The
patient’s osteoporosis treatment was continued, and
16 months after the sequestrectomy, further new bone
formation was observed (Fig. 6).
Discussion
We describe a case of a patient with a 6-year history of
alendronate therapy, in which BRONJ developed around
her dental implants. In this patient, the dental implants
achieved successful osseointegration, and BRONJ oc-
curred after the second surgery. Several factors could
have played a role in the development of BRONJ in this
patient. Glucocorticoid therapy is associated with an in-
creased risk of BRONJ. This may be a result of multiple
factors including inhibition of osteoblast function and
increased osteoblast and osteocyte apoptosis. Other
effects of glucocorticoids that may contribute to an in-
creased risk of BRONJ include increased bone resorp-
tion, immunosuppression, impaired wound healing, and
increased risk of local infection [10]. Patient-related local
risk factors include dentoalveolar surgery (e.g., tooth ex-
traction) and pre-existing inflammatory dental disease,
such as periodontal disease or periapical pathology [11].
Although BPs tend to accumulate in sites of active bone
remodeling, such as the jaws, the surgical trauma to the
alveolar bone during implant surgery could have further
stimulated the postoperative accumulation of the drug
in the implant site. The localized interference of BPs on
bone turnover may have influenced the peri-implant
bone resistance to oral bacteria in the long term, thus
increasing the risk of peri-implantitis. Once infection of
the implanted bone site is established, BPs further accu-
mulate because of the increased bone turnover; the
onsite activation of bisphosphonates will hamper the
healing capacity of bone, leading to bone necrosis and
sequestration [5].
Nevertheless, the role of the dental implant procedure
as a BRONJ pathogenetic factor [12–15] is still unclear.
Fig. 1 a Extraoral photograph showing an extraoral fistula in the right mandibular region. b Intraoral photograph showing an intraoral fistula on
the lingual side of the distal dental implants associated with mucosal inflammation and a purulent discharge
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Fig. 2 a Panoramic radiograph showing marked alveolar bone resorption surrounding the dental implant replacing the right mandibular first
molar (arrow). b Sagittal CT view. c Coronal CT view
Fig. 3 a Panoramic radiograph showing the sequestrum separation after 5 months of teriparatide therapy (arrows). b Sagittal CT view. c Coronal
CT view
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Recently, an increasing number of peri-implant BRONJs
have been described [5–9]. Peri-implant BRONJ has
been classified into two types: implant surgery-
triggered BRONJ, when it develops within 6 months
after implant surgery, suggesting that the surgical
process may be a contributing factor; and non-implant
surgery-triggered BRONJ, if it develops 6 months or
more after implant surgery, or when BP administra-
tion started after implant placement and osteointegra-
tion [8]. Most authors do not consider the surgical
procedure of implantation as a trigger factor for
MRONJ [7, 8, 14, 16–20].
It is therefore important that all patients treated
with oral BPs must be given a full explanation of the
potential risks of implant failure and BRONJ develop-
ment in the short and long term. Because the poten-
tial role of infection in implant failure and BRONJ
occurrence is still debated, great attention should be
paid to the long-term oral hygiene and plaque control
of implant-prosthetic restorations in patients taking
oral BPs.
BPs and other antiresorptives such as denosumab in-
crease apoptosis and inhibit osteoclast differentiation
and function, all leading to decreased bone resorption
and remodeling [11]. Teriparatide may counteract these
mechanisms by stimulating bone remodeling. It has been
shown to stimulate the activity and viability of osteo-
blasts from the alveolar bone of chronic bisphosphonate
users [21], while indirectly increasing the metabolic ac-
tivity and number of osteoclasts by affecting osteoblast
function [22]. An increased number of remodeling units
and increased bone formation within each unit may pro-
mote healing and the removal of damaged bone. Thus,
teriparatide may offer therapeutic promise for localized
bone defects of the jaw in patients with BRONJ [3, 23–25].
While it has been suggested recently that assertive sur-
gical removal of the sequestrum appears to be effective
[26–29], it can sometimes be difficult to distinguish liv-
ing bone from necrotic bone. Recently, resection of
BRONJ-affected tissue produced healing in patients
taking oral bisphosphonates more successfully than con-
servative management [30]. However, bone resection
Fig. 4 a Preoperative intraoral photograph. b Intraoperative photograph of the sequestrectomy. c Removal of the dental implant with a
specimen of the necrotic bone
Fig. 5 a Extraoral photograph 5 months after the sequestrectomy. b Intraoral photograph 5 months after the sequestrectomy.
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because of surgical treatment may lead to significant oral
disability.
Activation of living bone turnover by teriparatide
therapy causes progression of the separation of the
sequestrum. As a result, teriparatide therapy promotes
sequestrum separation followed by normal mucosal cover-
age of the exposed bone. After 5 months of teriparatide
therapy in our patient, sequestrum separation had pro-
gressed and thus a sequestrectomy was performed under
general anesthesia. After the wound in the affected area
had healed, our patient did not report any problems per-
taining to her ability to ingest food, despite the presence
of the bone defect in the mandible. We treated the patient
with teriparatide for 2 years. CT monitoring of the man-
dible would assist in determining whether teriparatide can
allow complete recovery of the bone defect in the man-
dible in cases of ONJ induced by bisphosphonates.
Conclusions
We have reported a case of a severely osteoporotic elderly
woman with BRONJ around her dental implants, who was
treated successfully with teriparatide. Teriparatide therapy
appeared to exert beneficial effects in this patient.
Funding
This report was supported by Grant-in-Aid for Researchers, Hyogo College of
Medicine, 2016.
Authors’ contributions
YZ and KT participated in the design of the study and drafted of the
manuscript. JT and MU participated in the acquisition of data. YZ and HK
participated in surgical treatment. KN and HK participated in the manuscript
review. All authors read and approved the final manuscript.
Authors’ information
YZ is a specialist in Oral and Maxillofacial Surgery and a research student of
the Department of Oral and Maxillofacial Surgery. KT and KN are associate
professors of the Department of Oral and Maxillofacial Surgery. JT is a
graduate student of the Department of Oral and Maxillofacial Surgery. MU is
a senior resident of the Department of Oral and Maxillofacial Surgery. HK is a
professor and chief of the Department of Oral and Maxillofacial Surgery.
Competing interests
Yusuke Zushi, Kazuki Takaoka, Joji Tamaoka, Miho Ueta, Kazuma Noguchi,
and Hiromitsu Kishimoto declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of
this case report and any accompanying images.
Received: 6 December 2016 Accepted: 12 February 2017
References
1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular
necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:
1115–7.
2. Marx RE, Sawatari J, Fortin M, et al. Bisphosphonate-induced exposed bone
(osteonecrosis/osteopetrosis) of the jaws; risk factors, recognition,
prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567.
3. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis
of the mandible: possible application for intermittent low-dose parathyroid
hormone [rhPTH(1- 34)]. J Oral Maxillofac Surg. 2007;65:573–80.
4. Madrid C, Sanz M. What influence do anticoagulants have on oral implant
therapy? A systematic review. Clin Oral Implants Res. 2009;20(Suppl4):96–106.
5. Bedogni A, Bettini G, Totola A, et al. Oral bisphosphonate-associated
osteonecrosis of the jaw after implant surgery: a case report and literature
review. J Oral Maxillofac Surg. 2010;68:1662–6.
6. Favia G, Piattelli A, Sportelli P, et al. Osteonecrosis of the posterior mandible
after implant insertion: a clinical and histological case report. Clin Implant
Dent Relat Res. 2011;13:58–63.
7. Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate-related
osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac
Surg. 2010;68:790–6.
8. Kwon TG, Lee CO, Park JW, et al. Osteonecrosis associated with dental
implants in patients undergoing bisphosphonate treatment. Clin Oral
Implants Res. 2014;25:632–40.
Fig. 6 a Panoramic radiograph 16 months after the sequestrectomy. b Sagittal CT view. c Coronal CT view. d 3D CT view
Zushi et al. International Journal of Implant Dentistry  (2017) 3:11 Page 5 of 6
9. Jacobsen C, Metzler P, Rössle M, et al. Osteopathology induced by
bisphosphonates and dental implants: clinical observations. Clin Oral Invest.
2013;17:167–75.
10. Saad F, Brown JE, Van PC, et al. Incidence, risk factors, and outcomes of
osteonecrosis of the jaw: integrated analysis from three blinded active-
controlled phase III trials in cancer patients with bone metastases. Ann
Oncol. 2012;23:1341–7.
11. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and
Maxillofacial Surgeons position paper on medication-related osteonecrosis
of the jaw-2014 update. J Oral Maxillofac Surg. 2015;73:1440.
12. Koka S, Babu NMS, Norell A. Survival of dental implants in post-menopausal
bisphosphonate users. J Prosthodont Res. 2010;54:108–11.
13. Bell BM, Bell RE. Oral bisphosphonates and dental implants: a retrospective
study. J Oral Maxillofac Surg. 2008;66:1022–4.
14. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental
implants in patients taking oral bisphosphonates: a review of 115 cases.
J Oral Maxillofac Surg. 2008;66:223–30.
15. Goss A, Bartold M, Sambrook P, Hawker P. The nature and frequency of
bisphosphonate-associated osteonecrosis of the jaws in dental implant
patients: a South Australian case series. J Oral Maxillofac Surg. 2010;68:
337–43.
16. Holzinger D, Seemann R, Matoni N, et al. Effect of dental implants on
bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg.
1937;2014(72):e1–8.
17. Madrid C, Sanz M. What impact do systemically administrated
bisphosphonates have on oral implant therapy? A systematic review. Clin
Oral Implants Res. 2009;20 Suppl 4:96–106.
18. Matsuo A, Hamada H, Takahashi H, et al. Evaluation of dental implants as a
risk factor for the development of bisphosphonate-related osteonecrosis of
the jaw in breast cancer patients. Odontology. 2016;104:363–71.
19. Vescovi P, Campisi G, Fusco V, et al. Surgery-triggered and non surgery-
triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a
retrospective analysis of 567 cases in an Italian multicenter study. Oral
Oncol. 2011;47:191–4.
20. Walter C, Al-Nawas B, Wolff T, et al. Dental implants in patients treated with
antiresorptive medication e a systematic literature review. Int J Implant
Dent. 2016;2:9.
21. Rao MV, Berk J, Almojaly SA, et al. Effects of platelet-derived growth
factor, vitamin D and parathyroid hormone on osteoblasts derived from
cancer patients on chronic bisphosphonate therapy. Int J Mol Med.
2009;23:407–13.
22. Charles JF, Aliprantis AO. Osteoclasts: more than ‘bone eaters’. Trends Mol
Med. 2014;20:449–59.
23. Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide
[recombinant human PTH-(1-34)] therapy. J Rheumatol. 2009;36:1835–7.
24. Cheung A, Seeman E. Teriparatide therapy for alendronate-associated
osteonecrosis of the jaw. N Engl J Med. 2010;363:2473–4.
25. Bashutski JD, Eber RM, Kinney JS, et al. Teriparatide and osseous
regeneration in the oral cavity. N Engl J Med. 2010;363:2396–405.
26. Abu-Id MH, Warnke PH, Gottschalk J, et al. “Bis-phossy jaws”—high and
low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
J Craniomaxillofac Surg. 2008;36:95–103.
27. Stanton DC, Balasanian E. Outcome of surgical management of
bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical
cases. J Oral Maxillofac Surg. 2009;67:943–50.
28. Carlson ER, Basile JD. The role of surgical resection in the management of
bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg.
2009;67:85–95.
29. Wilde F, Heufelder M, Winter K, et al. The role of surgical therapy in
the management of intravenous bisphosphonates-related osteonecrosis
of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:
153–63.
30. Silva LF, Curra C, Munerato MS, et al. Surgical management of
bisphosphonate-related osteonecrosis of the jaws: literature review. Oral
Maxillofac Surg. 2016;20:9–17.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Zushi et al. International Journal of Implant Dentistry  (2017) 3:11 Page 6 of 6
